Redeye comments on FluoGuide’s Q2 2025 report. The company’s recent progress update mostly aligned with our expectations, and we view its recent announcement of a collaboration with Olympus as encouraging. We judge the share’s next significant trigger will be the company’s phase II HNC interim readout in Q4 2025e, which could pave the way to pivotal trials in this indication.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/